intralesional rituximab in pemphigus vulgaris
Phase 3
- Conditions
- pemphigus vulgaris.Pemphigus vulgaris
- Registration Number
- IRCT20181224042105N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients with refractory lesions of pemphigus vulgaris in the scalp and oral cavity after 4 mounths of systemic therapy
No contraindication for rituximab
Exclusion Criteria
Any contraindication for rituximab
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of size variation in pemphigus lesions. Timepoint: Measurement of size of the lesions on day 1 and 30 and then mounth6. Method of measurement: Ruler and medical thermometer.
- Secondary Outcome Measures
Name Time Method Visual Analogue Scale. Timepoint: day 0 and 30 and then mounth6. Method of measurement: Asking from patient.